Streetbeat News

Revenues

CVNA

Carvana (NYSE:CVNA) has been analyzed by 8 analysts in the last three months, showing a mix of sentiments from bullish to bearish. The average 12-month price target for CVNA has risen 60.39% to $64.38, with a range from $45.00 to $90.00. Analysts from firms like Jefferies, RBC Capital, Morgan Stanley, JMP Securities, and Wedbush have adjusted their ratings and price targets, reflecting a nuanced view of Carvana's market position. Despite the positive adjustments in price targets, Carvana faces financial challenges, including a -14.56% decline in revenue growth, below-average net margin, ROE, and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 12:01 pm

DXCM

Analysts have diverse views on DexCom (NASDAQ:DXCM), with recent evaluations showing a mix of bullish and somewhat bullish ratings. The average 12-month price target for DXCM has been raised to $153.25, indicating an 11.32% increase from the previous target. DexCom's financials show strong performance with a revenue growth rate of 26.9% and high net margin, although its debt management poses challenges.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 12:01 pm

NHI

National Health Investors (NYSE:NHI) received mixed reviews from 4 analysts, with a shift towards more bullish sentiments in the last 30 days. The average 12-month price target is now $65.75, marking a 17.41% increase from the previous target of $56.00. The company's financial performance shows strong revenue growth, net margin, ROE, and ROA, with a lower-than-average debt-to-equity ratio, indicating a solid financial position.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 12:00 pm

DAL

Delta Air Lines CEO reports strong travel demand, with corporate travel returning. The company experienced 9 of its top 10 sales days in history within the last 10 weeks, indicating a significant recovery and growth in the travel sector.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:58 am

BVS

Bioventus projects its FY24 net sales to be between $520M-$535M, surpassing the estimated $517.82M. However, its adjusted EPS forecast of $0.12-$0.20 falls short of the expected $0.33.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:56 am

BVS

Bioventus forecasts its 2024 sales to range between $520M-$535M, surpassing the consensus estimate of $517.74M. However, its projected adjusted EPS of $0.12-$0.20 falls short of the consensus estimate of $0.33. The company also anticipates adjusted EBITDA to be between $89M-$94M.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:54 am

KLIC

Kulicke and Soffa Industries (KLIC) shares dropped following the announcement of the cancellation of Project W by one of its strategic partners, expected to reduce FY24 revenue results.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:38 am

BLDE

Blade Air Mobility projects its FY24 revenue to be between $240M-$250M, which is below the estimated $257.19M. Additionally, the company anticipates double-digit YoY revenue growth and double-digit Adjusted EBITDA for FY25.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:18 am

BLDE

Blade Air Mobility reported Q4 sales of $47.48M, missing the consensus estimate of $48.40M by 1.90%, but marking a 24.50% increase from the same period last year. The company also reported a net loss of $(33.94)M.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:15 am

MANU

Manchester United has reaffirmed its revenue guidance for 2024, projecting revenues to be in the range of £635 million to £665 million. This reiteration underscores the club's confidence in its financial outlook and strategic plans moving forward.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:03 am